Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | IDH2 | P48735 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305154 | 0.86 | NOTUM (0.52) | NOTUMCYP2C9CYP2C19POLBIDH2 | |
| SCHEMBL17305251 | 0.85 | MAPT (0.45) | NOTUMCYP2C9CYP2C19SERPINE1MAPT | |
| SCHEMBL5802557 | 0.84 | SERPINE1 (0.60) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL18700734 | 0.83 | FFAR4 (0.61) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL1573476 | 0.83 | NOTUM (0.57) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL17305385 | 0.83 | LGMN (0.53) | POLBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL18701232 | 0.81 | NOTUM (0.54) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL12644303 | 0.80 | FFAR2 (0.62) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL5800096 | 0.80 | FFAR2 (0.54) | NOTUMCYP2C9CYP2C19POLBSERPINE1 | |
| SCHEMBL19078354 | 0.78 | KMT2A (0.41) | NOTUMCYP2C9CYP2C19MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150578-B1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2015182723-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | NOTUM 2699/4885CYP2C9 1840/4885CYP2C19 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.